OP020 INHIBITION OF JAK 1/2 AS A POTENTIAL TARGET IN THE TREATMENT OF RECALCITRANT PYODERMA GANGRENOSUM: A CASE REPORT...European Wound Management Association (EWMA) Conference, May 3-5, 2023, Milan, Italy
Aim: Pyoderma Gangrenosum (PG) is a neutrophilic dermatosis that represents a clinical challenge because of the frequent recurrence of the disease. The aim of our work was to evaluate the use of Baricitinib, an oral JAK1/2 inhibitor, as a third-line biologic agent for the treatment of a multi-refrac...
| Publicado en: | Journal of Wound Management Vol. 24; no. 2; p. 392 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | abstract case study proceedings research Journal Article |
| Publicado: |
Cambridge Publishing
Jul2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |